Table 2.
Events (n) | Patients (n) | Intervention | Outcome | Reference |
2 | 400 | patients who were treated with recommended dosages of the drug for a mean of 8.7 years | incidence of hydroxychloroquine-related retinopathy | Mavrikakis et al [15] |
0 | 526 | hydroxychloroquine | retinal toxicity was noted during the first 6 years of treatment | Mavrikakis et al [15] |
46 | 845 | chloroquine, hydroxychloroquine, or both | ophthalmological alterations, confirmed by the ophthalmological examination | Spinelli et al [16] |
3 | 12 | 800 mg/day hydroxychloroquine | developed retinal toxicity with scotomas in the Amsler grid and Humphrey 10-2 automated perimetry, as well as abnormal multifocal electroretinography | Navajas et al [17] |
0 | 11 | long-term hydroxychloroquine | documented blindness, in all cases attributed to a cause other than hydroxychloroquine-related ocular toxicity | Singh et al [18] |
35 | 678 | hydroxychloroquine | had hydroxychloroquine toxicity | Chiu et al [19] |
1 | 121 | hydroxychloroquine | prevalence of toxic retinopathy | Cabral et al [20] |
18 | 59 | hydroxychloroquine | retinal toxicity was detected | Espandar et al [21] |
9 | 778 | antimalarial drugs | suffered definite presence of antimalarial retinopathy | Jover et al [22] |
11 | 36 | hydroxychloroquine | had abnormal response densities in one or both eyes | Maturi et al [23] |
3 | 26 | hydroxychloroquine | results from electrophysiological and clinical evaluation, toxicity (bull’s eye maculopathy) | Tzekov et al [24] |
4 | 93 | chloroquine and hydroxychloroquine therapy | developed typical bull’s eye maculopathy | Neubauer et al [25] |